Ptc Therapeutics (PTCT) Current Deferred Revenue (2012 - 2026)

Ptc Therapeutics' Current Deferred Revenue history runs 15 years deep, the most recent figure standing at $498000.0 for Q1 2026.

• In Q1 2026, Current Deferred Revenue fell 96.12% year-over-year to $498000.0; the TTM figure through Mar 2026 stood at $498000.0 (down 96.12% YoY), while the FY2025 annual figure was $2.0 million, down 62.94% from the prior year.
• Current Deferred Revenue was $498000.0 for Q1 2026 at Ptc Therapeutics, down from $2.0 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $12.8 million in Q1 2025 to a low of $214000.0 in Q1 2023.
• Historically, Current Deferred Revenue has averaged $3.6 million across 5 years, with a median of $1.5 million in 2022.
• The sharpest annual moves came in 2024 and 2026: Current Deferred Revenue surged 587.27% in 2024, then slumped 96.12% in 2026.
• A 5-year view of Current Deferred Revenue shows it stood at $1.4 million in 2022, then sank by 40.71% to $801000.0 in 2023, then soared by 587.27% to $5.5 million in 2024, then sank by 62.94% to $2.0 million in 2025, then plunged by 75.59% to $498000.0 in 2026.
• The last three Current Deferred Revenue figures came in at $498000.0 (Q1 2026), $2.0 million (Q4 2025), and $1.7 million (Q3 2025), per Business Quant data.